ArticleJournal for immunotherapy of cancer2023

XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer.

Kurt A Jenkins et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.